azacitidine has been researched along with ixazomib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Allen, JE; Babar, J; Benes, CH; Claxton, DF; Dicker, DT; El-Deiry, WS; Garnett, MJ; Grupp, SA; Hall, J; Khan, N; Kline, CLB; Lulla, AR; McDermott, U; Oster, W; Prabhu, VV; Pu, JJ; Talekar, MK; Van den Heuvel, APJ; Zhou, L | 1 |
3 other study(ies) available for azacitidine and ixazomib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Boron Compounds; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Glycine; Hematologic Neoplasms; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Mice; Mice, SCID; Pyridines; Pyrimidines; Transcription Factor CHOP; Transplantation, Heterologous | 2018 |